Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Metastatic Hormone Refractory Prostate Cancer Clinical Trial

Official title: Molecular, Genetic, and Genomic Assessments of MTOR Inhibition in Metastatic Hormone-Refractory Prostate Cancer Tissue From Patients Treated With RAD001

Status Completed

Clinical Trial Summary

The purpose of this study is to look at the genetic changes that RAD001 causes in prostate cancer cells and how those changes relate to patients' response to RAD001 treatment.

Clinical Trial Description

This correlative science study will be a minimum risk assessment of tumor and plasma samples collected as part of a Phase II clinical trial of RAD001 in patients with HRPC. Prior to enrollment or at the time of signing consent in the Phase II trial, patients will be approached to participate in the correlative science study. Patients who agree to participate will be assigned a separate study number which will be used to identify their molecular, genetic, genomic and biomarker assessments using the tumor and plasma samples. Clinical outcome results from the accompanying Phase II trial will be used for correlative assessments in this study, however, results from this correlative science study will be kept separate from the assessments and reporting of the clinical trial. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Metastatic Hormone Refractory Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT00636090
• Study type: Observational
• Source: Duke University
• Status: Completed
• Phase: N/A
• Start date: January 2007
• Completion date: January 2010